Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche Diagnostics unveils complete line of 9-Minute STAT assays
The new 9-minute STAT immunoassay tests include troponin T, troponin I, CK-MB, myoglobin and NT-proBNP and run on the cobas e 601 analyzer, part of the cobas 6000
The new 9-minute STAT immunoassay tests include troponin T, troponin I, CK-MB, myoglobin and NT-proBNP and run on the cobas e 601 analyzer, part of the cobas 6000
Pursuant to the license agreement, TAGI Pharma is expected to market and sell four Elite generic products in the US, Puerto Rico and Canada. Elite will receive a
The launch of the trial is based on the positive GFT505-209-4 and GFT505-109-6 studies, demonstrating the insulin-sensitizing effects of GFT505 in non-diabetic subjects. International scientific coordinator of the
Bivium plans to introduce Cellerate RX to the Panamian health-care community at the Congress of the Panamanian Association of General Surgery conference in Panama City. The addition of
NewCardio’s QTinno is a software suite that provides automated, comprehensive cardiac safety analysis as defined in the ICH E14 Guidance for Clinical Evaluation of QT/QTc interval prolongation and
The trial was a randomised, double-blind, placebo-controlled study in 150 patients to evaluate the safety, tolerability and efficacy of daily TT-223 treatments in combination with weekly administrations of
MIG, pursuant to the manufacturing agreement with Revolutions Medical, has guaranteed the production and delivery of a minimum of five million 3cc safety syringes per month for a
Pronova BioPharma’s first commercialized product is branded as Omacor in a number of countries throughout Europe and Asia and as Lovaza in the US. Pronova BioPharma CEO Morten
Novartis has licensed INC424 from Incyte for development and commercialisation outside the US, while the rights for the development and commercialisation of INC424 in the US are retained
NuGEN Technologies is the provider of RNA and DNA amplification and sample preparation technologies for genomic analysis. Initiated in 1948, the Framingham Heart Study is an epidemiological study,